Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Heinemann on Surrogate Markers Beyond PFS in Patients With CRC

July 14th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses surrogate markers aside from progression-free survival (PFS) in studying patients with colorectal cancer (CRC).

Immunotherapy Potential Continues to Grow in Gastric Cancers

July 14th 2016

Hendrik-Tobias Arkenau, MD, PhD, discusses the significance of the JAVELIN results for gastrointestinal cancer, the potential for CTLA-4 and PD-1/PD-L1 combinations, and the promise of pembrolizumab (Keytruda) in colorectal cancer.

Dr. Sharma on Results of SIRFLOX Study for CRC

July 14th 2016

Navesh K. Sharma, DO, PhD, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study, which examined the addition of Yttrium-90 (Y-90) resin microspheres (SIR-Spheres) to standard frontline FOLFOX-based chemotherapy with or without bevacizumab for patients with liver metastatic colorectal cancer (CRC).

A Closer Look at Tumor Location Analyses in Colon Cancer

July 14th 2016

Tumor Locations in CRC

July 14th 2016

A Closer Look at FIRE-3 and CALGB/SWOG 80405

July 14th 2016

First-line Targeted Therapies in Metastatic CRC

July 14th 2016

Practical Application of Molecular Testing in CRC

July 14th 2016

Personalized Medicine in Colorectal Cancer

July 14th 2016

Regorafenib Survival Benefit in RESORCE Changes HCC Paradigm

July 13th 2016

Topline results from the phase III RESORCE trial demonstrated that second-line treatment with regorafenib (Stivarga) represented a 38% reduction in the risk of death compared with best supportive care in patients with unresectable hepatocellular carcinoma.

Dr. Kanwal Raghav on the Biology of HER2 Gene Amplification in mCRC

July 13th 2016

Survival Outcomes Affected by Tumor Location in KRAS Wild-Type mCRC

July 12th 2016

The debate between the phase III CALGB/SWOG 80405 and FIRE-3 studies has been settled, as findings of a retrospective analysis of 80405 show that tumor location is significant in determining survival outcomes for patients with KRAS wild-type metastatic colorectal cancer.

Referring Patients with Colorectal Cancer to Clinical Trials

July 12th 2016

Role of TAS-102 (Trifluridine/tipiracil) in Advanced Colorectal Cancer

July 12th 2016

Colorectal Cancer: Regorafenib Patient Selection and Dosing

July 12th 2016

Goals of Therapy in Refractory Colorectal Cancer

July 12th 2016

Decisions in Colorectal Cancer Maintenance Therapy and Sequencing

July 12th 2016

Right- Versus Left-Sided Colorectal Tumors and Survival

July 12th 2016

Colorectal Cancer: Choosing a Biologic

July 12th 2016

Neoadjuvant and Adjuvant Therapy in Metastatic Colorectal Cancer

July 12th 2016